Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 19/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | CNR1 | P21554 | 4/20 | 0.42 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13605778 | 0.92 | CNR2 (0.48) | CNR2KCNH2CNR1P2RX3 | |
| SCHEMBL13605687 | 0.92 | CNR2 (0.49) | CNR2KCNH2CNR1P2RX3 | |
| SCHEMBL13605679 | 0.91 | CNR2 (0.53) | CNR2KCNH2CNR1P2RX3 | |
| SCHEMBL13605697 | 0.89 | CNR2 (0.55) | CNR2CNR1 | |
| SCHEMBL10048851 | 0.89 | CNR2 (0.45) | CNR2KCNH2CNR1P2RX3 | |
| SCHEMBL10048847 | 0.89 | CNR2 (0.49) | CNR2KCNH2CNR1 | |
| SCHEMBL13605683 | 0.88 | CNR2 (0.46) | CNR2KCNH2CNR1P2RX3 | |
| SCHEMBL10048934 | 0.86 | CNR2 (0.58) | CNR2KCNH2CNR1P2RX3 | |
| SCHEMBL10048908 | 0.85 | CNR2 (0.60) | CNR2KCNH2CNR1P2RX3 | |
| SCHEMBL13605709 | 0.84 | CNR2 (0.43) | CNR2KCNH2CNR1P2RX3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9284303-B2 | Benzimidazole cannabinoid agonists bearing a substituted heterocyclic group | JANSSEN PHARMACEUTICA N.V. (BE) | 2016-03-15 | — | — | US | disclosed |
| US-8524757-B2 | Benzimidazole cannabinoid agonists bearing a substituted heterocyclic group | JANSSEN PHARMACEUTICA NV (BE) | 2013-09-03 | — | — | US | disclosed |
| US-8524757-B2 | Benzimidazole cannabinoid agonists bearing a substituted heterocyclic group | JANSSEN PHARMACEUTICA NV (BE) | 2013-09-03 | — | — | US | disclosed |
| US-20090312339-A1 | BENZIMIDAZOLE CANNABINOID AGONISTS BEARING A SUBSTITUTED HETEROCYCLIC GROUP | JANSSEN PHARMACEUTICA NV (BE) | 2009-12-17 | — | — | US | disclosed |
| US-20090312339-A1 | BENZIMIDAZOLE CANNABINOID AGONISTS BEARING A SUBSTITUTED HETEROCYCLIC GROUP | JANSSEN PHARMACEUTICA NV (BE) | 2009-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312339-A1 | BENZIMIDAZOLE CANNABINOID AGONISTS BEARING A SUBSTITUTED HETEROCYCLIC GROUP | CNR1, CNR2, GPR18 | CNR2 2/4885KCNH2 1914/4885CNR1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.